Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Finance Minister Calls for Revision of Special Measures on Taxation “Without Preconceptions”
July 28, 2015
- Government Approves Basic Policy on Budget Requests for FY2016
July 28, 2015
- ICH Assembly to Make Final Decisions on All Important Issues: PMDA Official
July 27, 2015
- Japan Embarking on Biosimilar Development, but It’s a Race against Time: MHLW Official
July 24, 2015
- Japan Eyes Linking Dormant Pricing Premium with Sakigake System, Upping Rate to 20% at Maximum
July 24, 2015
- Chuikyo Subcommittee OKs Plan to Draft GL for Analyzing Cost-Effectiveness; QALY Expected to Be Main Index
July 24, 2015
- Drug Pricing Organization Proposes Re-Pricing of Products with Huge Sales
July 23, 2015
- Kaketsuken Withdraws Earlier Explanation of Blood Products Scandal; Problem Discovered through Information Provided to MHLW
July 23, 2015
- AMED Takes Initial Step Toward Out-Licensing First Lead Compound; Now Taking Applications from Companies
July 23, 2015
- PMDA Calls for Caution for Use of Inavir, Relenza in Patients Allergic to Milk Products
July 23, 2015
- MHLW Raises Flag on Vaccine Expiration Dates after Imovax Polio Mishaps
July 22, 2015
- MHLW Panel OKs Shipment of 2 Kaketsuken Blood Products
July 22, 2015
- Govt Sets FY2016 Budget Allocation Policy for Healthcare R&D
July 22, 2015
- Z2 Rule, DPC Incentive Need Revisions in Line with New Generic Target: MOF Budget Examiner
July 22, 2015
- Second Committee on Drugs to Discuss Approval of AZ’s Vandetanib at Meeting on Aug. 3
July 22, 2015
- Editor’s Pick: Five Healthcare News Headlines for July 6 - July 20
July 21, 2015
- PAFSC’s First Committee to Discuss Actelion’s Tracleer, Other Products on July 31
July 21, 2015
- Filings for Investigator-Led Trials Log 6-Fold Increase in 6 Years: PMDA Official
July 17, 2015
- Government’s Council Finalizes Policy Proposal for Promoting Genomic Medicines for Rare Diseases, Diabetes
July 16, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 2
July 15, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…